Download PDF
Endoscopy 2001; 33(2): 109-118
DOI: 10.1055/s-2001-11669
Review
© Georg Thieme Verlag Stuttgart · New York

Gastroesophageal Reflux Disease and Barrett's Esophagus

G. W. Falk
  • Center for Swallowing and Esophageal Disorders, Dept. of Gastroenterology, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
Further Information

Publication History

Publication Date:
31 December 2001 (online)

Also available at
    Permissions and Reprints

Gastroesophageal reflux disease (GERD) is a common clinical problem. Circumstantial evidence continues to suggest that infection with Helicobacter pylori may protect some patients from developing GERD and its complications. An empirical trial of a proton-pump inhibitor may now be a reasonable alternative to endoscopy or 24-hour pH testing for the diagnosis of GERD. Long-term follow-up data covering more than over a decade indicate that proton-pump inhibitors are effective and safe agents for the treatment of GERD. Furthermore, a strategy of proton-pump inhibitors first may be the most cost-effective approach to GERD. It remains unclear why some patients with GERD develop Barrett's esophagus, whereas others do not. Recent studies demonstrate the importance of pulses of acid or bile in increasing cell proliferation and cyclooxygenase-2 expression in Barrett's epithelium cell cultures. Short-segment Barrett's esophagus is now clearly associated with an increased risk of dysplasia or cancer compared to intestinal metaplasia of the cardia, and the cancer risk in this condition is similar to that with long-segment Barrett's esophagus. However, the overall cancer risk in patients with Barrett's esophagus is lower than previously estimated, at approximately 0.5 % annually. Ablation techniques continue to show promise, but are not yet ready for routine clinical use. Endoscopic mucosal resection is a new treatment option for selected patients with high-grade dysplasia or superficial esophageal adenocarcinoma.

References

  • 1 Valle C, Broglia F, Pistoria A, et al. Prevalence and impact of symptoms suggestive of gastroesophageal reflux disease.  Dig Dis Sci. 1999;  44 1848-1852
    CrossrefPubMedGoogle Scholar
  • 2 Henke C J, Levin T R, Henning J M, et al. Work loss due to peptic ulcer disease and gastroesophageal reflux disease in a health maintenance organization.  Am J Gastroenterol. 2000;  95 788-792
    CrossrefPubMedGoogle Scholar
  • 3 Lagergren J, Bergstrom R, Nyren O. No relation between body mass and gastro-oesophageal reflux symptoms in a Swedish population based study.  Gut. 2000;  47 26-29
    CrossrefPubMedGoogle Scholar
  • 4 Wilson L J, Ma W, Hirschowitz B I. Association of obesity with hiatal hernia and esophagitis.  Am J Gastroenterol. 1999;  94 2840-2844
    CrossrefPubMedGoogle Scholar
  • 5 Hu F, Preston P A, Post J C, et al. Mapping of a gene for severe pediatric gastroesophageal reflux to chromosome 13q14.  JAMA. 2000;  284 325-334
    CrossrefPubMedGoogle Scholar
  • 6 O'Connor H J. Helicobacter pylori and gastro-oesophageal reflux disease: clinical implications and management.  Aliment Pharmacol Ther. 1999;  13 117-127
    CrossrefPubMedGoogle Scholar
  • 7 Wu J C, Sung J J, Ng E K, et al. Prevalence and distribution of Helicobacter pylori in gastroesophageal reflux disease: a study from the East.  Am J Gastroenterol. 1999;  94 1790-1794
    CrossrefPubMedGoogle Scholar
  • 8 Haruma K, Hamada H, Mihara M, et al. Negative association between Helicobacter pylori infection and reflux esophagitis in older patients: case-control study in Japan.  Helicobacter. 2000;  5 24-29
    CrossrefPubMedGoogle Scholar
  • 9 Schenk B E, Kuipers E J, Klinkenberg-Knol E C, et al. Helicobacter pylori and the efficacy of omeprazole therapy for gastroesophageal reflux disease.  Am J Gastroenterol. 1999;  94 884-887
    CrossrefPubMedGoogle Scholar
  • 10 Wu J C, Sung J J, Chan F K. Helicobacter pylori infection is associated with milder gastro-oesophageal reflux disease.  Aliment Pharmacol Ther. 2000;  4 427-432
    PubMedGoogle Scholar
  • 11 El-Serag H B, Sonnenberg A, Jamal M M, et al. Corpus gastritis is protective against reflux oesophagitis.  Gut. 1999;  45 181-185
    PubMedGoogle Scholar
  • 12 Fallone C A, Barkun A N, Friedman G, et al. Is Helicobacter pylori eradication associated with gastroesophageal reflux disease?.  Am J Gastroenterol. 2000;  95 914-920
    CrossrefPubMedGoogle Scholar
  • 13 Vakil N, Hahn B, McSorley D. Recurrent symptoms and gastro-oesophageal reflux disease in patients with duodenal ulcer treated for Helicobacter pylori infection.  Aliment Pharmacol Ther. 2000;  14 45-51
    CrossrefPubMedGoogle Scholar
  • 14 McColl K E, Dickson A, El-Nujumi A, et al. Symptomatic benefit 1 - 3 years after H. pylori eradication in ulcer disease: impact of gastroesophageal reflux disease.  Am J Gastroenterol. 2000;  95 101-105
    PubMedGoogle Scholar
  • 15 Dent J, Brun J, Fendrick A M, et al. An evidence-based appraisal of reflux disease management: the Genval workshop report.  Gut. 1999;  (Suppl 2) S1-16
    PubMedGoogle Scholar
  • 16 Nandurkar S, Talley N J, Martin C J, et al. Esophageal histology does not provide additional useful information over clinical assessment in identifying reflux patients presenting for esophagogastroduodenoscopy.  Dig Dis Sci. 2000;  45 217-224
    CrossrefPubMedGoogle Scholar
  • 17 Fass R, Ofman J J, Gralnek I M, et al. Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease.  Arch Intern Med. 1999;  159 2161-2168
    CrossrefPubMedGoogle Scholar
  • 18 Fass R, Ofman J J, Sampliner R E, et al. The omeprazole test is as sensitive as 24-h oesophageal pH monitoring in diagnosing gastro-oesophageal reflux disease in symptomatic patients with erosive esophagitis.  Aliment Pharmacol Ther. 2000;  14 389-396
    CrossrefPubMedGoogle Scholar
  • 19 Fass R, Hell R, Sampliner R E, et al. Effect of ambulatory 24-hour esophageal pH monitoring on reflux-provoking activities.  Dig Dis Sci. 1999;  44 2263-2269
    CrossrefPubMedGoogle Scholar
  • 20 Klingler P J, Hinder R A, Wetscher G J, et al. Accurate placement of the esophageal pH electrode for 24-hour pH monitoring using a combined pH/manometry probe.  Am J Gastroenterol. 2000;  95 906-909
    CrossrefPubMedGoogle Scholar
  • 21 Kiljander T O, Salomaa E R, Hietanen E K, et al. Gastroesophageal reflux in asthmatics: a double-blind, placebo-controlled crossover study with omeprazole.  Chest. 1999;  116 1257-1264
    CrossrefPubMedGoogle Scholar
  • 22 Spivack H, Smith D, Phichith A, et al. Asthma and gastroesophageal reflux: fundoplication decreases need for systemic corticosteroids.  J Gastrointest Surg. 1999;  3 477-482
    CrossrefPubMedGoogle Scholar
  • 23 Ours T M, Kavuru M S, Schilz R J, Richter J E. A prospective evaluation of esophageal testing and a double-blind, randomized study of omeprazole in a diagnostic and therapeutic algorithm for chronic cough.  Am J Gastroenterol. 1999;  94 3131-3138
    CrossrefPubMedGoogle Scholar
  • 24 Gerson L B, Robbins A S, Garber A, et al. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease.  Am J Gastroenterol. 2000;  95 395-407
    CrossrefPubMedGoogle Scholar
  • 25 Richter J E, Campbell D R, Kahrilas P J, et al. Lansoprazole compared with ranitidine for the treatment of nonerosive gastroesophageal reflux disease.  Arch Intern Med. 2000;  160 1803-1809
    CrossrefPubMedGoogle Scholar
  • 26 Richter J E, Peura D, Benjamin S B, et al. Efficacy of omeprazole for the treatment of symptomatic acid reflux disease without esophagitis.  Arch Intern Med. 2000;  160 1810-1816
    CrossrefPubMedGoogle Scholar
  • 27 Klinkenberg-Knol E C, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa.  Gastroenterology. 2000;  118 661-669
    PubMedGoogle Scholar
  • 28 Lundell L, Miettinen P, Myrvold H E, et al. Lack of effect of acid suppression therapy on gastric atrophy.  Gastroenterology. 1999;  117 319-326
    CrossrefPubMedGoogle Scholar
  • 29 Gillen D, Wirz A A, Neithercut W D, et al. Helicobacter pylori infection potentiates the inhibition of gastric acid secretion by omeprazole.  Gut. 1999;  44 468-475
    PubMedGoogle Scholar
  • 30 Holtmann G, Cain C, Malfertheiner P. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole.  Gastroenterology. 1999;  117 11-16
    PubMedGoogle Scholar
  • 31 Bais J E, Bartelsman J F, Bonjer H J, et al. Laparoscopic or conventional Nissen fundoplication for gastro-oesophageal reflux disease: a randomised clinical trial.  Lancet. 2000;  355 170-174
    CrossrefPubMedGoogle Scholar
  • 32 Kamolz T, Bammer T, Wykpiel H, et al. Quality of life and surgical outcome after laparoscopic Nissen and Toupet fundoplication: one-year follow-up.  Endoscopy. 2000;  32 363-368
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Utley D S, Kim M, Vierra M A, Triadafilopoulos G. Augmentation of lower esophageal sphincter pressure and gastric yield pressure after radiofrequency energy delivery to the gastroesophageal junction: a porcine model.  Gastrointest Endosc. 2000;  52 81-86
    PubMedGoogle Scholar
  • 34 Eloubeidi M A, Provenzale D. Health-related quality of life and severity of symptoms in patients with Barrett's esophagus and gastroesophageal reflux disease without Barrett's esophagus.  Am J Gastroenterol. 2000;  95 1881-1887
    CrossrefPubMedGoogle Scholar
  • 35 Kaur B S, Ouatu-Lascar R, Omary M B, et al. Bile salts induce or blunt cell proliferation in Barrett's esophagus in an acid-dependent fashion.  Am J Physiol. 2000;  278 G1000-G1009
    PubMedGoogle Scholar
  • 36 Shirvani V N, Ouatu-Lascar R, Kaur B S, et al. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: ex vivo induction by bile salts and acid exposure.  Gastroenterology. 2000;  118 487-496
    PubMedGoogle Scholar
  • 37 Lord R V, Frommer D J, Inder S, et al. Prevalence of Helicobacter pylori infection in 160 patients with Barrett's oesophagus or Barrett's adenocarcinoma.  Aust NZ J Surg. 2000;  70 26-33
    CrossrefPubMedGoogle Scholar
  • 38 Weston A P, Badr A S, Topalovski M, et al. Prospective evaluation of the prevalence of gastric Helicobacter pylori infection in patients with GERD, Barrett's esophagus, Barrett's dysplasia, and Barrett's adenocarcinoma.  Am J Gastroenterol. 2000;  95 387-394
    PubMedGoogle Scholar
  • 39 Sampliner R E. Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus.  Am J Gastroenterol. 1998;  93 1028-1032
    CrossrefPubMedGoogle Scholar
  • 40 Soni A, Sampliner R E, Sonnenberg A. Screening for high-grade dysplasia in gastroesophageal reflux disease: is it cost-effective?.  Am J Gastroenterol. 2000;  95 2089-2093
    PubMedGoogle Scholar
  • 41 Ormsby A H, Vaezi M F, Richter J E, et al. Cytokeratin immunoreactivity patterns in the diagnosis of short-segment Barrett's esophagus.  Gastroenterology. 2000;  119 683-690
    PubMedGoogle Scholar
  • 42 Sharma P, Morales T G, Sampliner R E. Short segment Barrett's esophagus: the need for standardization of the definition and of endoscopic criteria.  Am J Gastroenterol. 1998;  93 1033-1036
    PubMedGoogle Scholar
  • 43 Sharma P, Weston A P, Morales T, et al. Relative risk of dysplasia for patients with intestinal metaplasia in the distal esophagus and in the gastric cardia.  Gut. 2000;  46 9-13
    CrossrefPubMedGoogle Scholar
  • 44 Rudolph R E, Vaughan T L, Storer B E, et al. Effect of segment length for neoplastic progression in patients with Barrett's esophagus.  Ann Intern Med. 2000;  132 612-620
    PubMedGoogle Scholar
  • 45 Lagergren J, Bergstrom R, Adami H O, et al. Association between medications that relax lower esophageal sphincter and risk for esophageal adenocarcinoma.  Ann Intern Med. 2000;  133 165-171
    PubMedGoogle Scholar
  • 46 O'Connor J B, Falk G W, Richter J E. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's esophagus registry .  Am J Gastroenterol. 1999;  94 2037-2042
    PubMedGoogle Scholar
  • 47 Shaheen N J, Crosby M A, Bozymski E M, Sandler R S. Is there publication bias in the reporting of cancer risk in Barrett's esophagus?.  Gastroenterology. 2000;  119 333-338
    CrossrefPubMedGoogle Scholar
  • 48 Levine D S, Blount P L, Rudolph R E, et al. Safety of a systematic endoscopic biopsy protocol in patients with Barrett's esophagus.  Am J Gastroenterol. 2000;  95 1152-1157
    CrossrefPubMedGoogle Scholar
  • 49 Falk G W, Ours T M, Richter J E. Practice patterns for surveillance of Barrett's esophagus in the USA.  Gastrointest Endosc. 2000;  52 197-203
    CrossrefPubMedGoogle Scholar
  • 50 Gross C P, Canto M I, Hixson J, et al. Management of Barrett's esophagus: a national study of practice patterns and their cost implications.  Am J Gastroenterol. 1999;  94 3340-3347
    PubMedGoogle Scholar
  • 51 Van Sandick J W, Bartelsman J F, Van Lanschot J J, et al. Surveillance of Barrett's oesophagus: physicians' practices and review of current guidelines.  Eur J Gastroenterol Hepatol. 2000;  12 111-117
    PubMedGoogle Scholar
  • 52 Provenzale D, Schmitt C, Wong J B. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk.  Am J Gastroenterol. 1999;  94 2043-2053
    CrossrefPubMedGoogle Scholar
  • 53 Weston A P, Badr A S, Hassanein R S. Prospective multivariate analysis of clinical, endoscopic, and histological factors predictive of the development of Barrett's multifocal high-grade dysplasia or adenocarcinoma.  Am J Gastroenterol. 1999;  94 3413-3419
    CrossrefPubMedGoogle Scholar
  • 54 Reid B J, Levine D S, Longton G, et al. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets.  Am J Gastroenterol. 2000;  95 1669-1676
    PubMedGoogle Scholar
  • 55 Weston A P, Sharma P, Topalovski M, et al. Long-term follow-up of Barrett's high-grade dysplasia.  Am J Gastroenterol. 2000;  95 1888-1893
    CrossrefPubMedGoogle Scholar
  • 56 Fass R, Sampliner R E, Malagon I B, et al. Failure of oesophageal acid control in candidates for Barrett's oesophagus reversal on a very high dose of proton pump inhibitor.  Aliment Pharmacol Ther. 2000;  14 597-602
    CrossrefPubMedGoogle Scholar
  • 57 Montes C G, Brandalise N A, Deliza R, et al. Antireflux surgery followed by bipolar electrocoagulation in the treatment of Barrett's esophagus.  Gastrointest Endosc. 1999;  5 173-177
    PubMedGoogle Scholar
  • 58 Pereira-Lima J C, Busnello J V, Saul C, et al. High power setting argon plasma coagulation for the eradication of Barrett's esophagus.  Am J Gastroenterol. 2000;  95 1661-1668
    PubMedGoogle Scholar
  • 59 Schulz H, Miehlke S, Antos D, et al. Ablation of Barrett's epithelium by endoscopic argon plasma coagulation in combination with high-dose omeprazole.  Gastrointest Endosc. 2000;  51 659-663
    CrossrefPubMedGoogle Scholar
  • 60 Krishnadath K K, Wang K K, Taniguchi K, et al. Persistent genetic abnormalities in Barrett's esophagus after photodynamic therapy.  Gastroenterology. 2000;  119 624-630
    CrossrefPubMedGoogle Scholar
  • 61 Van Laetham J L, Peny M O, Salmon I, et al. Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett's oesophagus.  Gut. 2000;  46 574-577
    CrossrefPubMedGoogle Scholar
  • 62 Ell C, May A, Gossner L, et al. Endoscopic mucosal resection of early cancer and high-grade dysplasia in Barrett's esophagus.  Gastroenterology. 2000;  118 670-677
    CrossrefPubMedGoogle Scholar
  • 63 Sabik J F, Rice T W, Goldblum J R, et al. Superficial esophageal carcinoma.  Ann Thorac Surg. 1995;  60 896-902
    CrossrefPubMedGoogle Scholar

Dr. G. W. Falk

Dept. of Gastroenterology, Desk S-40
The Cleveland Clinic Foundation

9500 Euclid Avenue
Cleveland, Ohio 44195
USA


Fax: Fax:+ 1-216-444-9416

Email: E-mail:falkg@ccf.org

      >